Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Sammy Huygens; Bas Oude Munnink; Arvind Gharbharan; Marion Koopmans; Bart Rijnders

doi:10.1093/cid/ciac601

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Sammy Huygens
, Bas Oude Munnink
, Arvind Gharbharan
, Marion Koopmans
, Bart Rijnders^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

72 Downloads (Pure)

Abstract

Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

Original language	English
Pages (from-to)	e507-e509
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume	76
Issue number	3
DOIs	https://doi.org/10.1093/cid/ciac601
Publication status	Published - 1 Feb 2023

Bibliographical note

Publisher Copyright:
© 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciac601Licence: CC BY-NC-ND

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron VariantFinal published version, 386 KBLicence: CC BY-NC-ND

Cite this

Huygens, S., Oude Munnink, B., Gharbharan, A., Koopmans, M., & Rijnders, B. (2023). Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), e507-e509. https://doi.org/10.1093/cid/ciac601

Huygens, Sammy ; Oude Munnink, Bas ; Gharbharan, Arvind et al. / Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 ; Vol. 76, No. 3. pp. e507-e509.

@article{3970f5cd7dda4b6d9c81419b96141f28,

title = "Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant",

abstract = "Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.",

author = "Sammy Huygens and \{Oude Munnink\}, Bas and Arvind Gharbharan and Marion Koopmans and Bart Rijnders",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2023",

month = feb,

day = "1",

doi = "10.1093/cid/ciac601",

language = "English",

volume = "76",

pages = "e507--e509",

journal = "Clinical infectious diseases : an official publication of the Infectious Diseases Society of America",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "3",

}

Huygens, S, Oude Munnink, B, Gharbharan, A, Koopmans, M & Rijnders, B 2023, 'Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 76, no. 3, pp. e507-e509. https://doi.org/10.1093/cid/ciac601

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. / Huygens, Sammy; Oude Munnink, Bas; Gharbharan, Arvind et al.
In: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, No. 3, 01.02.2023, p. e507-e509.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

AU - Huygens, Sammy

AU - Oude Munnink, Bas

AU - Gharbharan, Arvind

AU - Koopmans, Marion

AU - Rijnders, Bart

PY - 2023/2/1

Y1 - 2023/2/1

N2 - Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

AB - Viral evolution was evaluated in 47 immunocompromised patients treated with sotrovimab. Sequencing of SARS-CoV-2 following therapy was successful in 16. Mutations associated with sotrovimab resistance were documented in 6; viral replication continued after 30 days in 5. Combination antibody therapy may be required to avoid acquired resistance in immunocompromised patients.

UR - https://www.scopus.com/pages/publications/85138826295

U2 - 10.1093/cid/ciac601

DO - 10.1093/cid/ciac601

M3 - Article

C2 - 35867699

AN - SCOPUS:85138826295

SN - 1058-4838

VL - 76

SP - e507-e509

JO - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

IS - 3

ER -

Huygens S, Oude Munnink B, Gharbharan A, Koopmans M , Rijnders B. Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2023 Feb 1;76(3):e507-e509. doi: 10.1093/cid/ciac601

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this